Cadrenal Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
During the three months ended June 30, 2025, no officer or director of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “nonRule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as set forth below.
On May 9, 2025, each of Quang X. Pham and Matthew Szot, the Chief Executive Officer and Chief Financial Officer, respectively, of the Company, entered into written stock selling plans (the “10b5-1 Plans”) in accordance with Rule 10b5-1 of the Exchange Act and the Company’s Insider Trading Policy.
The 10b5-1 Plans entered into by Messrs. Pham and Szot allow for the sale of a maximum of 50,600 and 33,333 shares, respectively, of our common stock, over an approximate three and one-half month period subject to the terms and conditions of the 10b5-1 Plans, including specified minimum price and volume parameters. The term of Mr. Pham’s 10b5-1 Plan begins on August 13, 2025 through November 28, 2025. Mr. Szot’s 10b5-1 Plan begins on the third business day following the filing of this Quarterly Report and ends on November 30, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.